Company: LHI
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006939
Chunk: 52

Company: Living Homeopathy International Ltd.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 52
---
may be identified in the future. If Living Homeopathy identifies such issues or if Living Homeopathy is unable to produce accurate and
timely financial statements, its stock price may decline, and it may be unable to maintain compliance with the Nasdaq Listing Rules.

If Living Homeopathy ceases to qualify as a foreign private issuer, it would be required to comply fully with the reporting requirements of the Exchange Act applicable to U.S. domestic issuers, and it would incur significant additional legal, accounting and other expenses that it would not incur as a foreign private issuer.

Living Homeopathy expects to qualify as a foreign private issuer upon the completion of this offering. As a foreign private issuer, Living Homeopathy will be exempt from the rules under the Exchange Act prescribing the furnishing and content of proxy statements, and Living Homeopathy’s officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, Living Homeopathy will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as United States domestic issuers, and it will not be required to disclose in its periodic reports all of the information that United States domestic issuers are required to disclose. While Living Homeopathy currently expects to qualify as a foreign private issuer immediately following the completion of this offering, Living Homeopathy may cease to qualify as a foreign private issuer in the future.

Living Homeopathy is an “emerging growth company” within the meaning of the Securities Act, and if Living Homeopathy takes advantage of certain exemptions from disclosure requirements available to emerging growth companies, this could make it more difficult to compare Living Homeopathy’s performance with other public companies.

Living Homeopathy is an “emerging growth company” within the meaning of the Securities Act, as modified by the JOBS Act. Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that a company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable. Living Homeopathy has elected not to opt out of such extended transition period, which